Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it all mean to practitioners in the clinic?

Post test for CME/CE credit: https://elit.dkbmed.com/issues/195/test

Hosted on Acast. See acast.com/privacy for more information.